Investigational / not FDA-approved

Cardiogen

AEDR ultrashort peptide — never badge L-carnitine CID 10917; ≠ Cartalax AED.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Cardiogen in the Khavinson ultrashort-peptide literature is the tetrapeptide H-Ala-Glu-Asp-Arg-OH (AEDR). PubChem name “Cardiogen” resolves to L-carnitine (CID 10917) — wrong object; NEVER badge CID 10917 on this drawer. Prefer “AEDR — no clean CID.” No clean AEDR PubChem CID was locked in this pack. Cardiogen ≠ Cartalax (AED) ≠ L-carnitine ≠ Epitalon. Literature is thin, largely Khavinson-group cell-culture / gene-expression work. Human clinical RCTs are absent from this pack. This drawer marks papers. It is not use advice.

Bottom line

Object-matched evidence is a thin set of Russian short-peptide papers on AEDR stimulating cytoskeletal/nuclear-matrix protein expression and broader ultrashort-peptide differentiation / transport narratives. Refuse cardioprotective or anti-aging glow. Keep the L-carnitine PubChem trap visible.

Papers

AEDR / Cardiogen-line objects (thin primary set)

PMID 22977870 — Khavinson 2012

Tested: tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulating expression of cytoskeletal and nuclear matrix proteins (cell-culture / molecular framing).

Does not show: a human cardiomyopathy RCT or approved cardiac indication.

PMID 22808515 — Khavinson 2012

Tested: peptides tissue-specifically stimulating cell differentiation during aging (includes Cardiogen-line short peptides in program framing).

Does not show: modern controlled human cardiac outcomes.

PMID 36611900 — Khavinson 2022

Tested: narrative on SASP of cardiovascular system cells / inflammaging and perspectives of peptide regulation (program-level review; not AEDR-only RCT).

Does not show: pivotal human efficacy for Cardiogen.

PMID 36979488 — Khavinson 2023

Tested: feasibility of transport of 26 biologically active ultrashort peptides via LAT and PEPT family transporters (includes AEDR among a panel — transporter science).

Does not show: human clinical cardioprotection.

PMID 23581987 — Fedoreyeva 2013

Tested: interaction of short peptides (including Ala-Glu-Asp-Arg) with FITC-labeled wheat histones and oligonucleotide complexes (biophysical/lab object).

Does not show: human cardiac therapy.

Wrong object — L-carnitine PubChem trap (do not grade as Cardiogen)

No L-carnitine clinical papers are included as Cardiogen evidence. CID 10917 is explicitly out of scope.

What is not established

A clean PubChem CID for AEDR Cardiogen. Any controlled human cardiac efficacy. Equivalence to Cartalax, Epitalon, or L-carnitine. Anti-aging claims from ultrashort-peptide program reviews. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

22977870 22808515 36611900 36979488 23581987

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.